Wakame Stem,Wakame Stem Cut,Wakame Stem Seaweed,Pickled Pepper Wakame Stem DALIAN HAIBAO FOODS CO., LTD. , https://www.haibaoseafoods.com
Japanese Chinese and foreign pharmaceuticals listed A-type hemophilia drugs in Japan
According to "Japan Economic News" reported on May 23, Japan’s Chugai Pharmaceutical announced on May 22 that it has listed Hemlibra, a therapeutic drug for hemophilia A in Japan (common name emicizumab-kxwh). ). The drug is the first to be used in the treatment of hemophilia, and is expected to exceed 200 billion yen at the peak of global sales. Existing drugs need to be used 2 to 3 times a week, and it is reported that Hemlibra can be used once a week, which can reduce the burden on patients.
Hemlibra uses a "bispecific antibody" that binds one antibody to two antigens. One part of the antibody binds to Factor IX and the other part binds to Factor X to replace the function of Factor VIII.
When taking the medicine, firstly, subcutaneous injection is performed once every other week for 3 times per kilogram of body weight, for a total of 4 times, and then once a week for 1.5 mg per kilogram. The price of the drug is 30 mg 370,600 yen (about RMB 2,1600).
In addition, in order to be able to be used for patients without inhibitors, the company began to apply for additional licenses in April.
Hemophilia is a disease in which the protein "coagulation factor" that promotes blood coagulation in the blood does not fully function, resulting in a disease that is difficult to stop bleeding. Among the 11 clotting factors, the defect factor VIII belongs to type A hemophilia, and the defect factor IX belongs to type B hemophilia.
In the treatment of hemophilia A, Japan has been using the "Adynovate" of the Irish drug company Charles, but there are problems such as the frequency of administration and the inhibition of some patients.
Chinese and foreign pharmaceutical president Ogata Dalang said on the 22nd that "Hemlibra is a drug with an unprecedented mechanism of action and will make a huge contribution to patients with inhibitors."